- Start date
- 11 Jul 2024
- End date
- 12 Jul 2024
- Location
- Virtual Meeting
Live on11 Jul 2024 at 18:30 CEST
How to Access
Programme
18:30-19:30 CEST
Welcome and introduction, Scientific background and context
Amanda Psyrri, Attikon University Hospital, Athens, Greece
Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from cohort B (CPS less-than 1) of the TACTI-003 study
Robert Metcalf, The Christie NHS Foundation Trust, Manchester, UK
Critical analysis and perspectives
Marc Oliva, Institut Català d’Oncologia (ICO) L’Hospitalet, Barcelona, Spain
AACR Expert Commentary
Jong Chul Park, MGH – Massachusetts General Hospital, Boston, MA USA
Discussion and Q&A (i)
Faculty and online audience